title: Synthesis, cytotoxicity and protein kinase C inhibition of arylpyrrolylmaleimides.
abstract: A series of novel arylpyrrolylmaleimides was synthesized and evaluated for their in-vitro cytotoxicity against various human cancer cell lines and their protein-kinase C inhibitory activity. Some of the compounds showed high or moderate cytotoxic activity against the tested cell lines. Compound 6b is the most promising compound against the tested cancer cell lines; 6d and 6e showed moderate protein-kinase C inhibition. Structure-activity relationships are discussed based on the experimental data obtained.
authors.affiliation: ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
authors.forename: Gui-Qing
authors.initials: GQ
authors.lastname: Xu
authors.forename: Chong
authors.initials: C
authors.lastname: Zhang
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Xing-Lu
authors.initials: XL
authors.lastname: Zhou
authors.forename: Bo
authors.initials: B
authors.lastname: Yang
authors.forename: Qiao-Jun
authors.initials: QJ
authors.lastname: He
authors.forename: Yong-Zhou
authors.initials: YZ
authors.lastname: Hu
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D045744:Cell Line, Tumor; D006801:Humans; D008301:Maleimides / Q000138:chemical synthesis* / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D008301:Maleimides; D047428:Protein Kinase Inhibitors; D011493:Protein Kinase C